The Chemours Company (CC)
NYSE: CC · Real-Time Price · USD
20.31
+0.09 (0.45%)
At close: Jun 10, 2026, 4:00 PM EDT
20.50
+0.19 (0.94%)
After-hours: Jun 10, 2026, 7:00 PM EDT
The Chemours Company Revenue
The Chemours Company had revenue of $1.38B in the quarter ending March 31, 2026, with 0.95% growth. This brings the company's revenue in the last twelve months to $5.82B, up 0.55% year-over-year. In the year 2025, The Chemours Company had annual revenue of $5.81B with 0.45% growth.
Revenue (ttm)
$5.82B
Revenue Growth
+0.55%
P/S Ratio
0.52
Revenue / Employee
$1,021,228
Employees
5,700
Market Cap
3.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.81B | 26.00M | 0.45% |
| Dec 31, 2024 | 5.78B | -296.00M | -4.87% |
| Dec 31, 2023 | 6.08B | -753.00M | -11.02% |
| Dec 31, 2022 | 6.83B | 486.00M | 7.66% |
| Dec 31, 2021 | 6.35B | 1.38B | 27.69% |
| Dec 31, 2020 | 4.97B | -557.00M | -10.08% |
| Dec 31, 2019 | 5.53B | -1.11B | -16.75% |
| Dec 31, 2018 | 6.64B | 455.00M | 7.36% |
| Dec 31, 2017 | 6.18B | 783.00M | 14.50% |
| Dec 31, 2016 | 5.40B | -317.00M | -5.54% |
| Dec 31, 2015 | 5.72B | -715.00M | -11.12% |
| Dec 31, 2014 | 6.43B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Calumet | 4.17B |
| Cabot | 3.58B |
| H.B. Fuller Company | 3.46B |
| Avient | 3.28B |
| Minerals Technologies | 2.13B |
| Quaker Chemical | 1.93B |
| Ashland | 1.81B |
| Innospec | 1.79B |
CC News
- 19 days ago - Forget chips, liquid cooling may be the next big AI trade: these stocks are leading - Invezz
- 20 days ago - Chemours price target raised to $22 from $17 at JPMorgan - TheFly
- 4 weeks ago - Chemours price target raised to $30 from $24 at Alembic Global - TheFly
- 4 weeks ago - Chemours price target raised to $21 from $17 at Morgan Stanley - TheFly
- 4 weeks ago - Chemours price target raised to $29 from $26 at RBC Capital - TheFly
- 4 weeks ago - Chemours price target raised to $30 from $29 at UBS - TheFly
- 4 weeks ago - Chemours price target raised to $30 from $25 at Mizuho - TheFly
- 5 weeks ago - The Chemours Company Earnings Call Transcript: Q1 2026 - Transcripts